Literature DB >> 20378929

Effects of synthetic androgens on liver function using the rabbit as a model.

Sheri Ann Hild1, Barbara J Attardi, Sailaja Koduri, Bruce A Till, Jerry R Reel.   

Abstract

The objective of this study was to determine whether the rabbit was a suitable model to test new synthetic androgens for potential liver toxicity within a short dosing interval. Adult male rabbits were dosed orally daily on days 0-13 with 17α-methyltestosterone (MT) as a positive control and testosterone (T) as a negative control to validate this model. Synthetic androgens tested were: 7α-methyl-19-nortestosterone (MENT), dimethandrolone-undecanoate (DMAU), and 11β-methyl-19-nortestosterone-17β-dodecylcarbonate (11β-MNTDC). Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transpeptidase (GGT), and sorbitol dehydrogenase (SDH), as well as clearance of intravenous injected bromsulfonphthalein (BSP) from serum on days 0, 7, and 14, were determined. As expected, T (10 mg/kg/d) did not adversely affect BSP retention or serum liver enzymes. MT (10 mg/kg/d) increased BSP retention, and AST, ALT, GGT, and SDH levels, indicating that this model could detect androgens known to be hepatotoxic. DMAU and MENT (10 mg/kg/d) increased BSP retention and all 4 serum liver enzymes as well, but the effects were less than those observed with MT at the same dose. All parameters returned to baseline 2 weeks after cessation of dosing. 11β-MNTDC at 10 mg/kg/d did not have an effect on BSP retention or liver enzymes, but a slight increase in serum GGT levels was observed in rabbits treated with 25 mg/kg/d. For the androgens that exhibited liver toxicity at 10 mg/kg/d (MT, DMAU, and MENT), a no-observed-effect level of 1 mg/kg/d was established. Overall ranking of the synthetic androgens from most to least hepatotoxic on the basis of percent BSP retention was: MT & DMAU > MENT > 11β-MNTDC. Hence, the rabbit appears to be a promising model for detection of potential liver toxicity by synthetic androgens using BSP clearance and serum liver enzyme levels as early indicators of injury.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20378929      PMCID: PMC2943539          DOI: 10.2164/jandrol.109.009365

Source DB:  PubMed          Journal:  J Androl        ISSN: 0196-3635


  32 in total

1.  METHYLTESTOSTERONE, RELATED STEROIDS, AND LIVER FUNCTION.

Authors:  A A DELORIMIER; G S GORDAN; R C LOWE; J V CARBONE
Journal:  Arch Intern Med       Date:  1965-08

2.  Acute copper sulfate poisoning.

Authors:  H K Chuttani; P S Gupta; S Gulati; D N Gupta
Journal:  Am J Med       Date:  1965-11       Impact factor: 4.965

3.  Expression of kidney and liver bilitranslocase in response to acute biliary obstruction.

Authors:  Anabel Brandoni; Gisela Di Giusto; Raffaella Franca; Sabina Passamonti; Adriana M Torres
Journal:  Nephron Physiol       Date:  2010-01-21

4.  Circulating concentrations of the antiprogestins CDB-2914 and mifepristone in the female rhesus monkey following various routes of administration.

Authors:  J M Larner; J R Reel; R P Blye
Journal:  Hum Reprod       Date:  2000-05       Impact factor: 6.918

5.  The pharmacology and metabolism of testosterone undecanoate (TU), a new orally active androgen.

Authors:  A Coert; J Geelen; J de Visser; J van der Vies
Journal:  Acta Endocrinol (Copenh)       Date:  1975-08

6.  Bromsulphalein (BSP) kinetics in the rat: a new approach in evaluating experimental hepatotoxicity.

Authors:  G Molino; A Cavanna; A M Biondi; G Macrì; S Urigu; G Ugazio
Journal:  Int Arch Occup Environ Health       Date:  1982       Impact factor: 3.015

7.  Assessment of hepatic function in rabbits with steroid-induced cholestatic liver injury.

Authors:  B C Tennant; T Balazs; B H Baldwin; W E Hornbuckle; W L Castleman; U Boelsterli; F A Kallfelz
Journal:  Fundam Appl Toxicol       Date:  1981 Jul-Aug

8.  The effects of long-term administration of methyltestosterone on the development of liver lesions in BALB/c mice.

Authors:  W Taylor; S Snowball; M Lesna
Journal:  J Pathol       Date:  1984-07       Impact factor: 7.996

9.  Validation of an in vitro model for assessment of androstenedione hepatotoxicity using the rat liver cell line clone-9.

Authors:  Saura C Sahu; Paddy L Wiesenfeld; Chung S Kim; Ivan A Ross; Philip P Sapienza; Richard Newell; Michael W O'Donnell; Thomas J Flynn
Journal:  J Appl Toxicol       Date:  2008-07       Impact factor: 3.446

10.  Suspected cross-hepatotoxicity of flutamide and cyproterone acetate.

Authors:  Mireia Miquel; Aina Soler; Anna Vaqué; Isabel Ojanguren; Joan Costa; Ramon Planas
Journal:  Liver Int       Date:  2007-10       Impact factor: 5.828

View more
  10 in total

1.  Single, escalating dose pharmacokinetics, safety and food effects of a new oral androgen dimethandrolone undecanoate in man: a prototype oral male hormonal contraceptive.

Authors:  Prasanth Surampudi; Stephanie T Page; Ronald S Swerdloff; Jean Jacques Nya-Ngatchou; Peter Y Liu; John K Amory; Andrew Leung; Laura Hull; Diana L Blithe; Jason Woo; William J Bremner; Christina Wang
Journal:  Andrology       Date:  2014-05-02       Impact factor: 3.842

2.  Hormonal Male Contraception: Getting to Market.

Authors:  Stephanie T Page; Diana Blithe; Christina Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-03       Impact factor: 6.055

Review 3.  Continuing the search for a hormonal male contraceptive.

Authors:  Fiona Yuen; Brian T Nguyen; Ronald S Swerdloff; Christina Wang
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2020-02-19       Impact factor: 5.237

4.  Daily Oral Administration of the Novel Androgen 11β-MNTDC Markedly Suppresses Serum Gonadotropins in Healthy Men.

Authors:  Fiona Yuen; Arthi Thirumalai; Cindy Pham; Ronald S Swerdloff; Bradley D Anawalt; Peter Y Liu; John K Amory; William J Bremner; Clint Dart; Hongsheng Wu; Laura Hull; Diana L Blithe; Jill Long; Christina Wang; Stephanie T Page
Journal:  J Clin Endocrinol Metab       Date:  2020-03-01       Impact factor: 5.958

5.  Effects of 28 Days of Oral Dimethandrolone Undecanoate in Healthy Men: A Prototype Male Pill.

Authors:  Arthi Thirumalai; Jonas Ceponis; John K Amory; Ronald Swerdloff; Vijaya Surampudi; Peter Y Liu; William J Bremner; Eric Harvey; Diana L Blithe; Min S Lee; Laura Hull; Christina Wang; Stephanie T Page
Journal:  J Clin Endocrinol Metab       Date:  2019-02-01       Impact factor: 5.958

6.  Comparison of the single dose pharmacokinetics, pharmacodynamics, and safety of two novel oral formulations of dimethandrolone undecanoate (DMAU): a potential oral, male contraceptive.

Authors:  R Ayoub; S T Page; R S Swerdloff; P Y Liu; J K Amory; A Leung; L Hull; D Blithe; A Christy; J H Chao; W J Bremner; C Wang
Journal:  Andrology       Date:  2016-12-01       Impact factor: 4.456

Review 7.  Emerging approaches to male contraception.

Authors:  Arthi Thirumalai; John K Amory
Journal:  Fertil Steril       Date:  2021-04-27       Impact factor: 7.490

8.  An oral lipidic native testosterone formulation that is absorbed independent of food.

Authors:  John Newell-Price; Hiep Huatan; Jo Quirke; John Porter; Eleni Daniel; Enis Mumdzic; Bernard Voet; Brian Keevil; Martin J Whitaker; Richard J Ross
Journal:  Eur J Endocrinol       Date:  2021-10-05       Impact factor: 6.664

9.  Safety and Pharmacokinetics of Single-Dose Novel Oral Androgen 11β-Methyl-19-Nortestosterone-17β-Dodecylcarbonate in Men.

Authors:  Sherry Wu; Fiona Yuen; Ronald S Swerdloff; Youngju Pak; Arthi Thirumalai; Peter Y Liu; John K Amory; Feng Bai; Laura Hull; Diana L Blithe; Bradley D Anawalt; Toufan Parman; Kyuri Kim; Min S Lee; William J Bremner; Stephanie T Page; Christina Wang
Journal:  J Clin Endocrinol Metab       Date:  2019-03-01       Impact factor: 6.134

10.  Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling.

Authors:  Ramesh Narayanan; Sunjoo Ahn; Misty D Cheney; Muralimohan Yepuru; Duane D Miller; Mitchell S Steiner; James T Dalton
Journal:  PLoS One       Date:  2014-07-29       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.